Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells

Annals of the Rheumatic Diseases

Volumn 63, Issue 12, 2004, Pages 1632-1637

  Grisar, J ^a   Aringer, M ^a   Koller M D ^a   Stummvoll, G H ^a   Eselbock D ^a   Zwolfer B ^a   Steiner, C W ^a   Zierhut, B ^a   Wegner, L ^a   Pietschmann, P ^a   Smolen, J S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; CD18 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD69 ANTIGEN; CELL ADHESION MOLECULE; DEXAMETHASONE; DIHYDROOROTATE DEHYDROGENASE; HERMES ANTIGEN; HLA DR ANTIGEN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 3; PADGEM PROTEIN; URIDINE; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

ANTIRHEUMATIC AGENTS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HUMANS; HYALURONIC ACID; ISOXAZOLES; LEUKOCYTES, MONONUCLEAR; METHOTREXATE; URIDINE;

EID: 9644275490     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.018440     Document Type: Article

References (35)

1. Goronzy JJ, Weyand CM. Rheumatoid arthritis-epidemiology, pathology and pathogenesis. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, eds. Primer of the rheumatic diseases. Atlanta: Georgia Arthritis Foundation, 2001:209-18.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
3. Bell AL, Magill MK, McKane R, Irvine AE. Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid. Ann Rheum Dis 1995;54:910-15.
4. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996;23:1338-44.
5. Pietschmann P, Cush JJ, Lipsky PE, Oppenheimer-Marks N. Identification of subsets of human T cells capable of enhanced transendothelial migration. J Immunol 1992;149:1170-8.
6. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safely of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
7. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
8. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50:861-7.
9. Chong AS, Rezai K, Gebel HM, Finnegan A, Foster P, Xu X, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1990;61:140-5.
10. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999;162:2095-102.
11. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
12. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002;46:366-72.
13. Grisar J, Hahn P, Brosch S, Peterlik M, Smolen JS, Pietschmann P. Phenorypic characteristics of human monocytes undergoing transendothelial migration. Arthritis Res 2001;3:127-32.
14. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral t cells. J Clin Invest 1998;102:322-8.
15. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162:6473-81.
16. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995;44:317-22.
17. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld F, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1488-95.
18. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double blind placebo-controlled trial. Ann Intern Med 2002;137:726-33.
19. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-53.
20. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
21. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:495-505.
22. Koch MJ, Brennan DC. Leflunomide: is there a place for its use in transplantation? Curr Opin Organ Transplant 2003;8:317-22.
23. Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998;336:299-303.
24. Brown KL, Maiti A, Johnson P. Role of sulfation in CD44-mediated hyaluronan binding induced by inflammatory mediators in human CD14(+) peripheral blood monocytes. J Immunol 2001;167:5367-74.
25. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997;278:672-5.
26. Johnson P, Maiti A, Brown KL, Li R. A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response? Biochem Pharmacol 2000;59:455-65.
27. Mikecz K, Brennan FR, Kim JH, Giant TT. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995;1:558-63.
28. Nedvetzki S, Walmsley M, Alpert E, Williams RO, Feldmann M, Naor D. CD44 involvement in experimental collagen induced arthritis (CIA). J Autoimmun 1999;13:39-47.
29. Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum 1999;42:659-68.
30. Carpenito C, Pyszniak AM, Takei F. ICAM-2 provides a costimulatory signal for T cell stimulation by allogenic class II MHC. Scand J Immunol 1997;45:248-54.
31. Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. Inflamm Res 1996;45:550-6.
32. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9.
33. Rückemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;34:21682-91.
34. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-88.
35. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165:5962-9.